Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone–Inhibitory Effect of Octreotide after Growth Hormone–Releasing Hormone Stimulation
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 379 (3) , 400-408
Abstract
Acromegaly is a chronic systemic disease characterized by facial and peripheral changes caused by soft tissue overgrowth, together with multiple complications. Despite available surgical and medical therapies, suitable treatments for acromegaly are still lacking. Efficient drug development requires an understanding of the exposure-response (E-R) relationship based on non-clinical and early clinical studies. We aimed to establish a platform to facilitate the development of novel drugs to treat acromegaly. We evaluated the E-R relationship of the growth hormone (GH)-inhibitory effect of the somatostatin analogue, octreotide, under growth hormone-releasing hormone (GHRH) + arginine stimulation in healthy participants and compared the results with historical data for patients with acromegaly. This randomized five-way crossover study included two placebo and three active-treatment periods with different doses of octreotide acetate. GH secretion in the two placebo periods was comparable, confirming the reproducibility of the response with no carryover effect. GH secretion was inhibited by low-, medium-, and high-dose octreotide acetate, in a dose-dependent manner. We also examined the E-R relationship in monkeys as a preclinical drug evaluation study and in rats as a more convenient and simple system for screening candidate drugs. The E-R relationships and EC50 values were similar among animals, healthy paticipants and patients with acromegaly, which suggests that GH stimulation studies in early research and development stages allowed simulation of the drug responses in patients with acromegaly. Significance Statement We demonstrated similar exposure–response relationships in terms of the growth hormone-inhibitory effect of octreotide following growth hormone-releasing hormone stimulation among healthy participants, monkeys, and rats. The research methods and analyses utilized in this study will be useful for simulating the dosages and therapeutic effects of drugs for acromegaly, and will facilitate the research and development of novel therapeutic agents with similar modes of action.Keywords
This publication has 32 references indexed in Scilit:
- A Pituitary Society update to acromegaly management guidelinesPituitary, 2020
- Multidisciplinary management of acromegaly: A consensusReviews in Endocrine and Metabolic Disorders, 2020
- Gender has to be taken into account in diagnosing adult growth hormone deficiency by the GHRH plus arginine testGrowth Hormone & IGF Research, 2017
- Heterogeneity of the blood-brain barrierTissue Barriers, 2016
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialThe Lancet Diabetes & Endocrinology, 2014
- Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I studyEndocrine, 2012
- Somatostatin agonists for treatment of acromegalyMolecular and Cellular Endocrinology, 2008
- Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegalyClinical Pharmacology & Therapeutics, 2005
- Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertensionGastroenterology, 2001
- Agonist-induced Desensitization, Internalization, and Phosphorylation of the sst2A Somatostatin ReceptorJournal of Biological Chemistry, 1997